Alivus Life Sciences Ltd. News and Updates

Name: Latest research reports of Alivus Life Sciences Ltd. authored by AUM Capital and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 3
Author: AUM Capital

Keep track of all breaking news on Alivus Life Sciences Ltd. from all sources in a single place.

Load latest

Alivus Life Sciences Ltd.

24 Jul 2021

1111.20

-2.91%

Glenmark Life Sciences

IPO Note: Alivus Life Sciences Ltd.

AUM Capital

Glenmark Life Sciences (GLS) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufactures and sells Active Pharmaceutical Ingridients (APIs) for gastro-intestinal disorders, antiinfectives and other therapeutic areas. As of March 2021, GLS had a portfolio of 120 molecules globally and sold APIs in India and exported APIs to multiple countries in Europe, North America, Latin America,...

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

24 Jul 2021

1111.20

-2.91%

GLENMARK LIFE SCIENCES LTD

IPO Note: Alivus Life Sciences Ltd.

Ventura

IPO NOTE

Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.

Alivus Life Sciences Ltd.

23 Jul 2021

1111.20

-2.91%

Glenmark Life Sciences Ltd : IPO

IPO Note: Alivus Life Sciences Ltd.

ICICI Securities Limited

Leadership in select APIs, strong relation with large companies GLS is a leading developer, manufacturer of select high value, noncommoditised APIs in chronic therapeutic areas, including CVS, CNS & pain management, diabetes and continue to branch into other APIs. It has strong market share in select specialised APIs like Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). Total market size in sales terms for GLS' portfolio of 120 molecules globally was estimated at ~US$142 billion in 2020 and is expected to grow ~6.8% in the...

Alivus Life Sciences Ltd. is trading above all available SMAs

VOTE: Is Glenmark Life Sciences Ltd. worth buying?

123 Votes:

Buy 75.61%

Sell 13.01%

Hold 11.38%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf

46.99% Gain from 52W Low

Alivus Life Sciences Ltd. News and Updates

Keep track of all breaking news on Alivus Life Sciences Ltd. from all sources in a single place.